AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00655174
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this study arm will receive capsules that appear identical to those of the two study drugs but will contain no active ingredient.
Trial: NCT00470834
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: making placebo
Trial: NCT04456998
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching capsule containing placebo
Trial: NCT03258515
Drug: AZD6094 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A potent and selective small molecule mesenchymal epithelial transition (MET) kinase inhibitor with significant antitumor activity.
Trial: NCT01096862
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02765009
Drug: diuretics
RxNorm normalized name: DIURETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Used to reduce fluid overload as evidenced by weight gain
Trial: NCT01688531
Drug: CD0271 0.1%/CD1579 2.5% gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months
Trial: NCT01688531
Drug: CD0271 0.1%/CD1579 2.5% gel vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months
Trial: NCT02751385
Drug: Microgynon
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00285012
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg (placebo) by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days)
Trial: NCT02509117
Drug: Placebo single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched Placebo solution/suspension administered as single dose.
Trial: NCT02509117
Drug: Placebo multiple dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched Placebo (solution/suspension)administered daily for 14 consecutive days.
Trial: NCT01419197
Drug: Treatment of physician's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment of physician's choice (TPC) was a protocol-specified approved or standard of care therapy or combination of therapies, based on frequently used regimens for late-line HER2-positive metastatic breast cancer treatment after receipt of both trastuzumab- and lapatinib-containing regimens. The therapies included single-agent chemotherapy, single-agent (e.g., tamoxifen or aromatase inhibitor) or dual-agent (e.g., aromatase inhibitor with luteinizing hormone releasing hormone \[LHRH\] agonist) hormonal therapy for hormone receptor positive-disease, and HER2-directed therapy.~Participants who had documented progressive disease (PD) were eligible to switch treatment to receive trastuzumab emtansine 3.6 mg/kg. Participants who switched treatment remained on trastuzumab emtansine treatment until another PD event or unmanageable toxicity.~The formulation, storage, and preparation of all TPC were as per the appropriate package insert or national prescribing information.
Trial: NCT02366884
Drug: Anti-Bacterial Agents
RxNorm normalized name: INVESTIGATIONAL ANTI-BACTERIAL DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline, Paramomycin, Clarithromycin, Clindamycin, Dapsone, Miltefosine
Trial: NCT02366884
Drug: Anti-Fungal Agents
RxNorm normalized name: Aardora Anti-Fungal Maximum Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole, Amphotericin B liposomal, Fluconazole, Terbinafine, Voriconazole
Trial: NCT02366884
Drug: Anti-Protozoal Agents
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitazoxanide, Chloroquine, Albendazole, Ivermectin, Mebendazole, Metronidazole, Praziquantel, Levamisole
Trial: NCT02352285
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Start with 15mg to titrate upwards to 30mg to 60mg, once a daily
Trial: NCT02175927
Drug: Tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antibiotic of classical quadruple therapy
Trial: NCT02873195
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02838329
Drug: Ropivicaine
RxNorm normalized name: Ropivicaine-Sufentanil Citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01685151
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00125528
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo bid
Trial: NCT02874144
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: looks like AZ compound, made by same company, double blind. 40 mg three times daily po for 12 weeks
Trial: NCT00003497
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
Trial: NCT01269242
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bindarit-matching placebo tablets for 6 months.
Trial: NCT03564704
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CTX will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
Trial: NCT03564704
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be added to Consolidation-Module of PDT-ALL-LBL protocol.
Trial: NCT03564704
Drug: 6-mercaptopurine.
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mercaptopurine will be added to Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
Trial: NCT01461109
Drug: [18F] CFPyPB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of \[18F\]CFPyPB or 5 μg of CFPyPB (whichever is greatest).
Trial: NCT00666484
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00666484
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00666484
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04109885
Drug: Paracervical injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine.
Trial: NCT01578850
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etanercept placebo once weekly + methotrexate with or without other DMARDs
Trial: NCT01232803
Drug: 2% N-9 gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
Trial: NCT01232803
Drug: HEC Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
Trial: NCT01318005
Drug: Oral Contraceptive: Ortho-Novum® 1/35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Contraceptive: Ortho-Novum® 1/35, pill, 2-3 mos, daily.
Trial: NCT01318005
Drug: Oral Contraceptive: Ovcon® 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Contraceptive: Ovcon® 35, pill, 2-3 mos, daily.
Trial: NCT01318005
Drug: Oral Contraceptive: Microgestin Fe® 1/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Contraceptive: Microgestin Fe® 1/20, pill, 2-3 mos, daily.
Trial: NCT00637988
Drug: Rofecoxib
RxNorm normalized name: Rofecoxib
DrugBank: Rofecoxib (DB00533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg once daily
Trial: NCT03849625
Drug: aspirin, NSAIDs, paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perform skin test and/or provocation test with aspirin, paracetmol, or suspected NSAIDs in questionable cases
Trial: NCT00464971
Drug: estradiol, 25 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04278872
Drug: SJX-653
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered orally once daily
Trial: NCT04278872
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered orally once daily
Trial: NCT02042573
Drug: SSRI (SEROPLEX ou ZOLOFT)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00967954
Drug: antiandrogen therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02500940
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neoadjuvant chemotherapy regimen with Fluorouracil
Trial: NCT02500940
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neoadjuvant chemotherapy regimen with Leucovorin
Trial: NCT02183168
Drug: Meloxicam suppository
RxNorm normalized name: meloxicam Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02183168
Drug: Meloxicam tablet
RxNorm normalized name: Meloxicam Tablets
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02183168
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00576940
Drug: Reconvan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isocaloric, immunomodulating entral diet
Trial: NCT00576940
Drug: Peptisorb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isocaloric, isopeptic standard diet
Trial: NCT01642862
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of pharmacokinetic parameters of different formulations (liquid vs tablet) and doses (20 or 40 mg) of simvastatin after single oral administration of the drug
Trial: NCT00241059
Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04423107
Drug: Acetaminophen, Ibuprofen, Oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (Tylenol) 15 mg/kg q6h, Ibuprofen q6h, and Oxycodone 0.1 mg/kg q6h
Trial: NCT03371095
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Use of cyclophosphamide
Trial: NCT00006050
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00006050
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006050
Drug: isolated perfusion
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00006050
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00685009
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill daily
Trial: NCT02335814
Drug: FLX925
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00160667
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral dose of two equal intakes.
Trial: NCT00123253
Drug: TH9507
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03456882
Drug: RNS60
RxNorm normalized name: Ronasin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline plus oxigen in nanobubble
Trial: NCT03083457
Drug: General anesthetic
RxNorm normalized name: General anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia with a standard protocol
Trial: NCT00239135
Drug: PEP005
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03083457
Drug: Fluid administration
RxNorm normalized name: Fluid Administration Set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-5 ml/kg of balanced crystalloids will be administered throughout the whole surgical procedure
Trial: NCT00118495
Drug: Non-prescription Zestra(TM): patented formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03772288
Drug: NKTR-214
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion.
Trial: NCT02872285
Drug: Drug: LYC-30937-EC
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02872285
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01407380
Drug: PWT33597 mesylate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PWT33597 taken orally daily for 28 consecutive days in 28 day cycle
Trial: NCT00534599
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00554710
Drug: methylprednisolone or budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: methylprednisolone 32 mg followed by taper or budesonide 9 mg/day followed by taper
Trial: NCT02553356
Drug: PT2385
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03629275
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham surgical comparator includes stereotactic surgery and a partial thickness burr hole drilled into the skull. No injection of any kind is made into the brain, and no other intervention is given.
Trial: NCT02392377
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02392377
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00985127
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered daily for 21 days
Trial: NCT01760785
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses will be titrated over the first four days of study in the same manner as the active study drug. After titration, the research pharmacy may increase the dose by 1 tablet per day, in the same fashion that the active drug may be adjusted, so that the participant and clinical team remain blinded to the drug assignment. The research pharmacy may also reduce the daily dosage back down by one tablet per day for the same reason.
Trial: NCT01349049
Drug: PLX3397
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximum Tolerated Dose of PLX3397 will be administered orally, twice daily.
Trial: NCT01349049
Drug: PLX3397
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug product is available in capsule form, to be taken orally.
Trial: NCT00807859
Drug: AMG 386 30 mg/kg, Capecitabine and Lapatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 386 30 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
Trial: NCT04330729
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Se arm description
Trial: NCT03257800
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group which received intravenously the same volume with normal saline one minute prior propofol 3mg.kg-¹ and 1 min before LMA insertion in propofol group
Trial: NCT01505764
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets identical in appearance to active tablets; oral administration once a day for 84 days, at least 1 hour before the first meal of the day.
Trial: NCT01717053
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH analog (at discretion of treating physician) will be administered over 6 months (for example, leuprolide acetate 22.5mg IM or goserelin acetate 10.8mg SC given every 3 months for 2 doses).
Trial: NCT00757198
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: remifentanil infusion
Trial: NCT01595022
Drug: Placebo: Flexi ring FR01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrauterine device, inserted once for 3 months
Trial: NCT01595022
Drug: Placebo: Flexi ring FR20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrauterine device, inserted once for 3 months
Trial: NCT00662298
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg of prednisolone once a day for 14 days
Trial: NCT05782309
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessement, supplementation placebo for 30 days with either Placebo or Flavanols, Re-assessment
Trial: NCT00902486
Drug: INCB028050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg capsules QD
Trial: NCT02527603
Drug: Anti-Inflammatory Agents, Non-Steroidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will be administered a dose of NSAI intra-muscular or orally (Dexketoprofen, Enantyum®) it is part of the normal treatment of these patients to cope with pain.
Trial: NCT00902486
Drug: INCB028050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 mg capsules QD
Trial: NCT00902486
Drug: INCB028050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg capsule QD
Trial: NCT00902486
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching INCB028050 QD
Trial: NCT01758536
Drug: Huatuo Zaizao Pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A tens of herbs botanical drug product 12 gram (g) in 72 mini pills formulation. It is to be used as 12 g each time, twice daily.
Trial: NCT00413985
Drug: Nutrient-enriched human milk
RxNorm normalized name: human milk preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03007810
Drug: Hemay005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized into 6 cohorts(10mg, 20mg, 40mg, 80mg, 120mg, 180mg) orally single dose
Trial: NCT03007810
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized into 5 cohorts(20mg, 40mg, 80mg, 120mg, 180mg) orally single dose
Trial: NCT00803673
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo '719
Trial: NCT00366067
Drug: Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04059536
Drug: Acetylsalicylic Acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT04059536
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Injection
Trial: NCT01131013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo in capsules administered as a single oral dose.
Trial: NCT03085914
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin
Trial: NCT03085914
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide
Trial: NCT03594110
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken daily with or without food
Trial: NCT03090152
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPCA: Saline.
Trial: NCT04494100
Drug: Lidocaine + Epinephrine
RxNorm normalized name: epinephrine / lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WALANT technique with 1% lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine
Trial: NCT00228176
Drug: Placebo (for Rimonabant)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral administration
Trial: NCT04504851
Drug: Rosuvastatin 10mg
RxNorm normalized name: ROSUVASTATIN 10MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10mg of Rosuvastatin in the Intensive Phase of Therapy (8 weeks)
Trial: NCT01786070
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00317967
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg pills daily
Trial: NCT00505076
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets placebo BID
Trial: NCT02215941
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04076098
Drug: Minocycline Hydrochloride
RxNorm normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of Periocline gel into the periodontal pockets will be carried out until it overflows the pockets
Trial: NCT01541397
Drug: Sapropterin
RxNorm normalized name: Sapropterin
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy
Trial: NCT03472846
Drug: Prolia, 60 Mg/mL Subcutaneous Solution
RxNorm normalized name: Prolia, 60 mg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antiresorptive treatment with Prolia